Merck and BioNTech are further expanding their strategic partnership to accelerate the supply of urgently needed lipids for the production of the Pfizer-BioNTech Covid-19 Vaccine (BNT162b2).
Merck, in close collaboration with BioNTech, will significantly accelerate the supply of urgently needed lipids and increase the amount of lipid delivery towards the end of 2021.
Lipids are critical to the drug delivery system of mRNA therapies to the body for a vaccine to be effective. Only very few companies in the world are currently able to produce custom lipids in significant quantities and according to the highest quality requirements needed for vaccine production.
“What unites BioNTech and Merck is our strong belief in mRNA technology and our trustful collaboration in vaccine development,” said Stefan Oschmann, Chairman of the Executive Board and CEO of Merck.
“We are convinced that now is the time to pull together to supply as much vaccine as possible to the world. Extraordinary times like these require bold steps, and we are ready to take these steps to tackle one of the biggest challenges of humanity.”